Figure 4, Panel A: Plots of plaque reduction neutralizing antibody geometric mean titers by time (days) post vaccination when VR-1508 is used as the assay antigen. Subjects who did not receive the second vaccination were excluded in the results for Days 42, 56, 112, 140 and 182. Subjects who did not receive the third vaccination were excluded in the results for Days 140 and 182.
Groups: A. 2×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax
B. 5×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax
C. 1×10^8 SC IMVAMUNE/IMVAMUNE/Dryvax
D. SC Placebo/Placebo/Dryvax
E. 1×10^8 SC IMVAMUNE/IMVAMUNE/Placebo
F. 1×10^8 IM IMVAMUNE/IMVAMUNE/Dryvax
Subjects who did not receive the second vaccination were excluded in the results for Days 42, 56, 112, 140, 182.
Subjects who did not receive the third vaccination were excluded in the results for Days 140, 182.
Figure 4, Panel B: Plots of plaque reduction neutralizing antibody geometric mean titers by time (days) post vaccination when Dryvax® is used as the assay antigen. Subjects who did not receive the second vaccination were excluded in the results for Days 42, 56, 112, 140 and 182. Subjects who did not receive the third vaccination were excluded in the results for Days 140 and 182.
Subjects who did not receive the second vaccination were excluded in the results for Days 42, 56, 112, 140, 182.
Subjects who did not receive the third vaccination were excluded in the results for Days 140, 182.
Groups: A. 2×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax
B. 5×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax
C. 1×10^8 SC IMVAMUNE/IMVAMUNE/Dryvax
D. SC Placebo/Placebo/Dryvax
E. 1×10^8 SC IMVAMUNE/IMVAMUNE/Placebo
F. 1×10^8 IM IMVAMUNE/IMVAMUNE/Dryvax
Figure 4, Panel C: Plots of ELISA antibody geometric mean titers by time (days) post-vaccination when IMVAMUNE® is used as the assay antigen. Subjects who did not receive the second vaccination were excluded in the results for Days 42, 56, 112, 140 and 182. Subjects who did not receive the third vaccination were excluded in the results for Days 140 and 182.
Subjects who did not receive the second vaccination were excluded in the results for Days 42, 56, 112, 140, 182.
Subjects who did not receive the third vaccination were excluded in the results for Days 140, 182.
Groups: A. 2×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax
B. 5×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax
C. 1×10^8 SC IMVAMUNE/IMVAMUNE/Dryvax
D. SC Placebo/Placebo/Dryvax
E. 1×10^8 SC IMVAMUNE/IMVAMUNE/Placebo F. 1×10^8 IM IMVAMUNE/IMVAMUNE/Dryvax
Figure 4, Panel D: Plots of ELISA antibody geometric mean titer by time (days) when Dryvax® is used as the assay antigen. Subjects who did not receive the second vaccination were excluded in the results for Days 42, 56, 112, 140 and 182. Subjects who did not receive the third vaccination were excluded in the results for Days 140 and 182.
Subjects who did not receive the second vaccination were excluded in the results for Days 42, 56, 112, 140, 182.
Subjects who did not receive the third vaccination were excluded in the results for Days 140, 182.
Groups: A. 2×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax
B. 5×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax
C. 1×10^8 SC IMVAMUNE/IMVAMUNE/Dryvax
D. SC Placebo/Placebo/Dryvax
E. 1×10^8 SC IMVAMUNE/IMVAMUNE/Placebo
F. 1×10^8 IM IMVAMUNE/IMVAMUNE/Dryvax
Figure 4, Panel E: Plot of ELISPOT results by time (days) post-vaccination when Dryvax® is used as the assay antigen. Subjects who did not receive the second vaccination were excluded in the results for Days 56, 112, 140 and 365. Subjects who did not receive the third vaccination were excluded in the results for Days 140 and 365.
Subjects who did not receive the second vaccination were excluded in the results for Days 42, 56, 112, 140.
Subjects who did not receive the third vaccination were excluded in the results for Day 140.
Groups: A. 2×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax
B. 5×10^7 SC IMVAMUNE/IMVAMUNE/Dryvax
C. 1×10^8 SC IMVAMUNE/IMVAMUNE/Dryvax
D. SC Placebo/Placebo/Dryvax
E. 1×10^8 SC IMVAMUNE/IMVAMUNE/Placebo
F. 1×10^8 IM IMVAMUNE/IMVAMUNE/Dryvax